Galectin Therapeutics Inc. Common Stock GALT
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T16:01:39.376Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-01-15
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T16:00:33.358389516Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T15:56:49.044509+00:00
Galectin Therapeutics Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 11.89 | 232.2% | 283.9% | |||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 3.54 | 189.2% | 26.5% | |||
| 45Δ | 3.70 | 177.9% | 23.8% | |||
| 50Δ | 3.86 | 166.7% | 21.0% | |||
| 55Δ | 4.01 | 155.4% | 18.3% | |||
| 60Δ | 4.17 | 144.2% | 15.5% | |||
| 65Δ | 4.33 | 132.9% | 12.7% | |||
| 70Δ | 4.49 | 121.7% | 10.0% | |||
| 75Δ | 4.65 | 110.4% | 7.2% | |||
| 80Δ | 4.81 | 99.2% | 4.5% | |||
20Δ
- Pseudo strike
- 11.89
- IV
- 232.2%
- B/E move
- 283.9%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.54
- IV
- 189.2%
- B/E move
- 26.5%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.70
- IV
- 177.9%
- B/E move
- 23.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.86
- IV
- 166.7%
- B/E move
- 21.0%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.01
- IV
- 155.4%
- B/E move
- 18.3%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.17
- IV
- 144.2%
- B/E move
- 15.5%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.33
- IV
- 132.9%
- B/E move
- 12.7%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.49
- IV
- 121.7%
- B/E move
- 10.0%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.65
- IV
- 110.4%
- B/E move
- 7.2%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.81
- IV
- 99.2%
- B/E move
- 4.5%
Options history
No recorded observations
Biotechnology
GANX
Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. The company is…
More →GENB
Generate Biomedicines, Inc. is an innovative biotechnology company at the forefront of protein therapeutics development, leveraging advanced genetic engineering and artificial…
More →GERN
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The…
More →GHRS
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The…
More →GLUE
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively…
More →GMAB
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
More →